Blood Glucose Target Before and During Exercise in Adults With Type 1 Diabetes Using an Artificial Pancreas (GUARDIA)
Type 1 Diabetes
About this trial
This is an interventional prevention trial for Type 1 Diabetes focused on measuring Artificial pancreas, Exercice, Hypoglycemia
Eligibility Criteria
Inclusion Criteria: Males and females aged between 18 and 65 years old. Clinical diagnosis of type 1 diabetes for 1 year. (Note: The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.) Treatment using DIY-AID system for 3 months. Own a smartphone or tablet to use the mobile application: Keenoa, Fitbit App Using Dexcom G6 and willing to share CGM data with the research team. Using rapid- (e.g., Aspart, Lispro or Glulisine) or ultra-rapid (e.g., FiAsp) acting insulin analogs. HbA1c < 8.5%. Exclusion Criteria: Major complication within the previous 3 months (e.g., severe hypoglycemia requiring assistance, diabetic ketoacidosis, or cardiovascular event). Restriction in PA due to significant diabetes complications (e.g., severe peripheral neuropathy, active proliferative retinopathy, etc.) or other type of limitations (e.g., orthopedic, severe arthritis, etc.). Uncontrolled hypertension (e.g., blood pressure > 150 mmHg systolic or > 95 mmHg diastolic). Ongoing pregnancy or breastfeeding. Inability to give consent.
Sites / Locations
- Institut de recherches cliniques de MontréalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Temporary target of 8.3 mmol/L
Temporary target of 8.8 mmol/L
Temporary target of 9.3 mmol/L
Current commercial artificial pancreas thresholds. Temporary target set 60 minutes before the intervention.
Temporary target set 60 minutes before the intervention
Temporary target set 60 minutes before the intervention